We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $253.21 · 19 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Jazz Pharmaceuticals PLC (JAZZ): CBD-Based Epidiolex Drug Sales Up 15% - Yahoo Finance
Jazz Pharmaceuticals PLC (JAZZ): CBD-Based Epidiolex Drug Sales Up 15% Yahoo Finance
A Look At Jazz Pharmaceuticals (JAZZ) Valuation After A Strong Multi Period Share Price Run - simplywall.st
A Look At Jazz Pharmaceuticals (JAZZ) Valuation After A Strong Multi Period Share Price Run simplywall.st
Jazz Pharmaceuticals plc (JAZZ) seeks votes on director elections, share‑issuance powers - Stock Titan
Jazz Pharmaceuticals plc (JAZZ) seeks votes on director elections, share‑issuance powers Stock Titan
Jazz Pharmaceuticals (JAZZ) director Anne O’Riordan will not seek re-election after 2026 - Stock Titan
Jazz Pharmaceuticals (JAZZ) director Anne O’Riordan will not seek re-election after 2026 Stock Titan
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 04. | After market close (AMC) | $6.18 | — | — | $1.11B | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $-1.52 | — | — | $897.8M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $5.63 | — | — | $2.98B | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $2.35 | — | — | $1.93B | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 28. | Barclays | — | Maintain | Overweight → Overweight | — | Barclays: Overweight |
| 2026. 05. 22. | Bernstein | — | Initiate coverage | — → Market Perform | — | Bernstein: Market Perform |
| 2026. 05. 22. | Piper Sandler | — | Maintain | Overweight → Overweight | — | Piper Sandler: Overweight |
| 2026. 05. 20. | UBS | — | Upgrade | Neutral → Buy | — | UBS: Neutral → Buy |
| 2026. 05. 07. | TD Cowen | — | Maintain | Buy → Buy | — | TD Cowen: Buy |
| 2026. 05. 07. | RBC Capital | — | Maintain | Outperform → Outperform | — | RBC Capital: Outperform |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 358,634 | $67.8B | 0.12% | — | New position |
| 2 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 175,000 | $29.75B | 0.05% | — | New position |
| 3 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 19,600 | $3.71B | 0.00% | — | New position |
| 4 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 2,400 | $408M | 0.00% | — | New position |